Metabolomics approaches in pancreatic adenocarcinoma : tumor metabolism profiling predicts clinical outcome of patients
BACKGROUND: Pancreatic adenocarcinomas (PAs) have very poor prognoses even when surgery is possible. Currently, there are no tissular biomarkers to predict long-term survival in patients with PA. The aims of this study were to (1) describe the metabolome of pancreatic parenchyma (PP) and PA, (2) determine the impact of neoadjuvant chemotherapy on PP and PA, and (3) find tissue metabolic biomarkers associated with long-term survivors, using metabolomics analysis.
METHODS: 1H high-resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) spectroscopy using intact tissues was applied to analyze metabolites in PP tissue samples (n = 17) and intact tumor samples (n = 106), obtained from 106 patients undergoing surgical resection for PA.
RESULTS: An orthogonal partial least square-discriminant analysis (OPLS-DA) showed a clear distinction between PP and PA. Higher concentrations of myo-inositol and glycerol were shown in PP, whereas higher levels of glucose, ascorbate, ethanolamine, lactate, and taurine were revealed in PA. Among those metabolites, one of them was particularly obvious in the distinction between long-term and short-term survivors. A high ethanolamine level was associated with worse survival. The impact of neoadjuvant chemotherapy was higher on PA than on PP.
CONCLUSIONS: This study shows that HRMAS NMR spectroscopy using intact tissue provides important and solid information in the characterization of PA. Metabolomics profiling can also predict long-term survival: the assessment of ethanolamine concentration can be clinically relevant as a single metabolic biomarker. This information can be obtained in 20 min, during surgery, to distinguish long-term from short-term survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
BMC medicine - 15(2017), 1 vom: 16. März, Seite 56 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Battini, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5KV86114PT |
|---|
| Anmerkungen: |
Date Completed 05.06.2017 Date Revised 13.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12916-017-0810-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM26988260X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM26988260X | ||
| 003 | DE-627 | ||
| 005 | 20231227125541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12916-017-0810-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1223.xml |
| 035 | |a (DE-627)NLM26988260X | ||
| 035 | |a (NLM)28298227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Battini, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolomics approaches in pancreatic adenocarcinoma |b tumor metabolism profiling predicts clinical outcome of patients |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.06.2017 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Pancreatic adenocarcinomas (PAs) have very poor prognoses even when surgery is possible. Currently, there are no tissular biomarkers to predict long-term survival in patients with PA. The aims of this study were to (1) describe the metabolome of pancreatic parenchyma (PP) and PA, (2) determine the impact of neoadjuvant chemotherapy on PP and PA, and (3) find tissue metabolic biomarkers associated with long-term survivors, using metabolomics analysis | ||
| 520 | |a METHODS: 1H high-resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) spectroscopy using intact tissues was applied to analyze metabolites in PP tissue samples (n = 17) and intact tumor samples (n = 106), obtained from 106 patients undergoing surgical resection for PA | ||
| 520 | |a RESULTS: An orthogonal partial least square-discriminant analysis (OPLS-DA) showed a clear distinction between PP and PA. Higher concentrations of myo-inositol and glycerol were shown in PP, whereas higher levels of glucose, ascorbate, ethanolamine, lactate, and taurine were revealed in PA. Among those metabolites, one of them was particularly obvious in the distinction between long-term and short-term survivors. A high ethanolamine level was associated with worse survival. The impact of neoadjuvant chemotherapy was higher on PA than on PP | ||
| 520 | |a CONCLUSIONS: This study shows that HRMAS NMR spectroscopy using intact tissue provides important and solid information in the characterization of PA. Metabolomics profiling can also predict long-term survival: the assessment of ethanolamine concentration can be clinically relevant as a single metabolic biomarker. This information can be obtained in 20 min, during surgery, to distinguish long-term from short-term survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a HRMAS | |
| 650 | 4 | |a Long-term survival | |
| 650 | 4 | |a Metabolomics | |
| 650 | 4 | |a NMR | |
| 650 | 4 | |a Pancreatic adenocarcinoma | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Ethanolamine |2 NLM | |
| 650 | 7 | |a 5KV86114PT |2 NLM | |
| 700 | 1 | |a Faitot, F |e verfasserin |4 aut | |
| 700 | 1 | |a Imperiale, A |e verfasserin |4 aut | |
| 700 | 1 | |a Cicek, A E |e verfasserin |4 aut | |
| 700 | 1 | |a Heimburger, C |e verfasserin |4 aut | |
| 700 | 1 | |a Averous, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bachellier, P |e verfasserin |4 aut | |
| 700 | 1 | |a Namer, I J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC medicine |d 2003 |g 15(2017), 1 vom: 16. März, Seite 56 |w (DE-627)NLM143503421 |x 1741-7015 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2017 |g number:1 |g day:16 |g month:03 |g pages:56 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12916-017-0810-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2017 |e 1 |b 16 |c 03 |h 56 | ||